Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial

详细信息    查看全文

• 作者：Remigio M Olveda ; MD<sup>asup> ; Luz P Acosta ; PhD<sup>asup> ; Veronica Tallo ; PhD<sup>csup> ; Palmera I Baltazar ; MD<sup>asup> ; Jenny Lind S Lesiguez ; MD<sup>asup><sup> ; sup><sup>bsup> ; Georgette G Estanislao ; MD<sup>asup><sup> ; sup><sup>bsup> ; Edna B Ayaso ; MD<sup>asup><sup> ; sup><sup>bsup> ; Donna Bella S Monterde ; MD<sup>asup><sup> ; sup><sup>bsup> ; Antonio Ida ; MD<sup>asup> ; Nora Watson ; PhD<sup>dsup> ; Emily A McDonald ; PhD<sup>esup><sup> ; sup><sup>fsup> ; Hannah W Wu ; PhD<sup>esup><sup> ; sup><sup>fsup> ; Prof Jonathan D Kurtis ; PhD<sup>esup><sup> ; sup><sup>gsup> ; Prof Jennifer F Friedman ; PhD<sup>esup><sup> ; sup><sup>fsup><sup> ; sup><sup>Jennifer_Friedman@Brown.edu" class="auth_mail" title="E-mail the corresponding authorsup>
• 刊名：The Lancet Infectious Diseases
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：16
• 期：2
• 页码：199-208
• 全文大小：215 K

文摘

Despite WHO recommendations to offer pregnant women treatment with praziquantel, many nations continue to withhold treatment, awaiting data from controlled trials addressing safety and efficacy. The objectives of this study were to assess whether treatment of pregnant women with schistosomiasis at 12&ndash;16 weeks gestation leads to improved maternal and newborn outcomes and to collect maternal and newborn safety data.

sSec_2">Methods

spara90">This phase 2, randomised, double-blind, placebo-controlled trial was done in 72 baranguays (villages) serviced by six municipal health centres in a schistosomiasis endemic region of northeastern Leyte, Philippines. Pregnant women (at 12&ndash;16 weeks gestation) who were otherwise healthy but infected with Schistosoma japonicum were enrolled and randomly assigned (1:1) to receive either over-encapsulated praziquantel (total dose 60 mg/kg given as two split doses) or placebo. Participants, investigators, midwives, and laboratory staff were all masked to treatment. The primary outcome was birthweight. Safety data were collected including immediate reactogenicity, post-dosing toxicology ascertained 24 h after study drug administration, and maternal and newborn serious adverse events. Analysis followed the intention-to-treat principle. Analyses were done using hierarchical generalised linear models to adjust for identified confounders and account for potential clustering of observations within villages and municipalities. This trial is registered with <span id="interrefs10" class="interref" data-locatorType="url" data-locatorKey="http://ClinicalTrials.gov">ClinicalTrials.govspan>, number <span id="interrefs20" class="interref" data-locatorType="ctgov" data-locatorKey="NCT00486863">NCT00486863span>.

sSec_3">Findings

spara100">Between Aug 13, 2007, and Dec 3, 2012, 370 pregnant women were enrolled and randomly assigned to each treatment group (184 to the placebo group, 186 to the praziquantel group). Most women had low-intensity infections (n=334, 90%). Treatment with praziquantel did not have a significant effect on birthweight (2·85 kg in both groups, β=&minus;0·002 [95% CI &minus;0·088 to 0·083]; p=0·962). Treatment was well tolerated with reactogenicity rates similar to those seen in non-pregnant participants (severe reactions occurred in five patients in the praziquantel group and two in the placebo group, and included headache, fever, and malaise). There were no significant differences in key safety outcomes including abortion, fetal death in utero, and congenital anomalies.

sSec_4">Interpretation

spara110">Results from this study provide important data from a controlled trial in support of the expansion of treatment policies to include pregnant women as recommended by WHO.

sSec_5">Funding

spara120">National Institutes of Health, National Institute of Allergy and Infectious Diseases (U01AI066050).